Wayfinding Financial’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.42M Sell
5,660
-10
-0.2% -$2.15K 0.54% 38
2026
Q1
$1.23M Sell
5,670
-144
-2% -$31.9K 0.54% 41
2025
Q4
$1.33M Buy
5,814
+8
+0.1% +$1.82K 0.56% 37
2025
Q3
$1.34M Sell
5,806
-140
-2% -$28.5K 0.58% 37
2025
Q2
$1.17M Sell
5,946
-340
-5% -$63.2K 0.52% 37
2025
Q1
$1.32M Sell
6,286
-53
-0.8% -$10.3K 0.58% 33
2024
Q4
$1.13M Buy
+6,339
New +$1.17M 0.6% 34
2024
Q3
Sell
-6,656
Closed -$1.14M 38
2024
Q2
$1.14M Sell
6,656
-36
-0.5% -$5.96K 0.64% 32
2024
Q1
$1.07M Buy
6,692
+153
+2% +$26.4K 0.63% 33
2023
Q4
$1.01M Buy
6,539
+19
+0.3% +$2.77K 0.69% 32
2023
Q3
$966K Buy
6,520
+117
+2% +$17.2K 0.73% 29
2023
Q2
$965K Sell
6,403
-160
-2% -$23.5K 0.67% 28
2023
Q1
$1.05M Buy
6,563
+553
+9% +$84.5K 0.8% 23
2022
Q4
$817K Sell
6,010
-262
-4% -$40.2K 0.66% 30
2022
Q3
$841K Buy
6,272
+21
+0.3% +$3.01K 0.79% 22
2022
Q2
$957K Buy
6,251
+3
+0% +$458 0.84% 21
2022
Q1
$954K Buy
6,248
+238
+4% +$34.6K 0.8% 20
2021
Q4
$817K Buy
+6,010
New +$710K 0.66% 30

Other funds holding ABBV

Wayfinding Financial's ABBV Position: Q2 2026 in Review

Wayfinding Financial reduced its AbbVie (ABBV) stake by 0.18% in Q2 2026, selling an estimated $2.15K and leaving 5,660 shares worth $1.42M. The position accounts for 0.54% of the portfolio, ranked #38.

Wayfinding Financial first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. 4,206 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Wayfinding Financial held 5,660 shares of AbbVie worth $1.42M as of Q2 2026.
  • Wayfinding Financial sold 10 AbbVie shares in Q2 2026, an estimated $2.15K.
  • AbbVie made up 0.54% of Wayfinding Financial's portfolio in Q2 2026, its #38 holding.
  • Wayfinding Financial first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
  • 4,206 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Wayfinding Financial's 13F filing for Q2 2026, filed 13 Aug 2026.